6.215
Relay Therapeutics Inc stock is traded at $6.215, with a volume of 842.40K.
It is down -4.23% in the last 24 hours and up +56.02% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
See More
Previous Close:
$6.50
Open:
$6.6
24h Volume:
842.40K
Relative Volume:
0.45
Market Cap:
$1.07B
Revenue:
$25.55M
Net Income/Loss:
$-341.97M
P/E Ratio:
-2.2196
EPS:
-2.8
Net Cash Flow:
$-304.44M
1W Performance:
+11.36%
1M Performance:
+56.02%
6M Performance:
+157.23%
1Y Performance:
-8.46%
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
RLAY
Relay Therapeutics Inc
|
6.22 | 1.12B | 25.55M | -341.97M | -304.44M | -2.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.56 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
469.33 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.46 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
800.99 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
330.86 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-04-25 | Resumed | Guggenheim | Buy |
Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
Sep-10-24 | Resumed | Goldman | Buy |
Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
Apr-13-23 | Initiated | Raymond James | Outperform |
Feb-03-23 | Initiated | Oppenheimer | Outperform |
Sep-30-22 | Initiated | Barclays | Equal Weight |
Sep-02-22 | Initiated | Stifel | Buy |
Jun-06-22 | Initiated | Jefferies | Underperform |
Feb-01-22 | Initiated | Berenberg | Buy |
Jul-21-21 | Initiated | BofA Securities | Buy |
Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
Nov-05-20 | Initiated | H.C. Wainwright | Buy |
Aug-10-20 | Initiated | Cowen | Outperform |
Aug-10-20 | Initiated | Goldman | Buy |
Aug-10-20 | Initiated | Guggenheim | Buy |
Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Using Bollinger Bands to evaluate Relay Therapeutics Inc.2025 Risk Factors & Daily Chart Pattern Signals - newser.com
Key metrics from Relay Therapeutics Inc.’s quarterly dataTrade Risk Assessment & Free Daily Entry Point Trade Alerts - newser.com
What MACD and RSI say about Relay Therapeutics Inc.Weekly Stock Summary & Smart Money Movement Alerts - newser.com
Will Relay Therapeutics Inc. stock benefit from green energy trendsWeekly Trend Report & Verified Technical Trade Signals - newser.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Relay Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Review & Comprehensive Market Scan Reports - newser.com
Relay Therapeutics Inc. stock prediction for this weekEntry Point & Weekly High Potential Alerts - newser.com
Multi asset correlation models including Relay Therapeutics Inc.Market Sentiment Summary & Weekly Momentum Stock Picks - newser.com
Relay Therapeutics (NASDAQ:RLAY) Trading Up 7.5%Should You Buy? - MarketBeat
Can trapped investors hope for a rebound in Relay Therapeutics Inc.July 2025 Opening Moves & Capital Protection Trade Alerts - newser.com
Can a trend reversal in Relay Therapeutics Inc. lead to recoveryMarket Risk Report & Capital Efficiency Focused Ideas - newser.com
Short interest data insights for Relay Therapeutics Inc.July 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Is Relay Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Gains Summary & Smart Investment Allocation Tips - newser.com
Does Relay Therapeutics Inc. qualify in momentum factor screening2025 Volatility Report & Weekly High Momentum Picks - newser.com
Is Relay Therapeutics Inc. stock poised for growth2025 Price Momentum & Reliable Entry Point Trade Alerts - newser.com
Is Relay Therapeutics Inc. stock bottoming outWatch List & Free Verified High Yield Trade Plans - newser.com
Relay Therapeutics, Inc. $RLAY Shares Sold by Voya Investment Management LLC - Defense World
Is Relay Therapeutics Inc a good long term investmentPrice Action Analysis & Affordable Market Trading - earlytimes.in
What analysts say about Relay Therapeutics Inc stockPrice Action Analysis & Affordable Market Growth - earlytimes.in
Relay Therapeutics (NASDAQ:RLAY) Shares Up 7%Time to Buy? - MarketBeat
Institutional scanner results for Relay Therapeutics Inc.July 2025 Short Interest & Weekly High Conviction Trade Ideas - newser.com
Relay Therapeutics (NASDAQ:RLAY) Trading 7.9% HigherTime to Buy? - MarketBeat
Relative strength of Relay Therapeutics Inc. in sector analysisTrade Signal Summary & Safe Entry Zone Identification - newser.com
Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608 - Yahoo Finance
Analysts Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Price Target at $16.50 - MarketBeat
Acadian Asset Management LLC Buys 653,081 Shares of Relay Therapeutics, Inc. $RLAY - MarketBeat
Goldman Sachs Group Inc. Sells 627,974 Shares of Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Volatility Watch: Can Relay Therapeutics Inc expand its profit marginsMarket Movement Recap & Expert Verified Stock Movement Alerts - khodrobank.com
History Review: What are Relay Therapeutics Incs growth leversEarnings Miss & Low Risk Growth Stock Ideas - خودرو بانک
Bull Bear: Whats the beta of Relay Therapeutics Inc stockWeekly Investment Summary & Long-Term Safe Return Strategies - خودرو بانک
Growth Value: Should I hold or sell REGCO now2025 Market Trends & Fast Gain Swing Alerts - khodrobank.com
Aug Opening: Is Unifi Inc. subject to activist investor interestVolume Spike & Advanced Swing Trade Entry Alerts - khodrobank.com
Aug Spikes: Can Relay Therapeutics Inc expand into new markets2025 Trading Volume Trends & Stepwise Trade Execution Plans - خودرو بانک
Growth Review: Will Relay Therapeutics Inc benefit from government policy2025 Short Interest & Weekly Top Performers Watchlists - خودرو بانک
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relay Therapeutics Inc Stock (RLAY) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Rahmer Peter | See remarks |
Jul 28 '25 |
Sale |
3.74 |
1,359 |
5,083 |
393,722 |
Catinazzo Thomas | Chief Financial Officer |
Jul 29 '25 |
Sale |
3.68 |
18,380 |
67,638 |
335,295 |
Catinazzo Thomas | Chief Financial Officer |
Jul 28 '25 |
Sale |
3.74 |
1,701 |
6,362 |
353,675 |
Bergstrom Donald A | President, R&D |
Jul 29 '25 |
Sale |
3.68 |
26,701 |
98,260 |
552,720 |
Bergstrom Donald A | President, R&D |
Jul 28 '25 |
Sale |
3.74 |
4,069 |
15,218 |
579,421 |
Adams Brian | Chief Legal Officer |
Jul 29 '25 |
Sale |
3.68 |
18,276 |
67,256 |
371,472 |
Adams Brian | Chief Legal Officer |
Jul 28 '25 |
Sale |
3.74 |
1,637 |
6,122 |
389,748 |
Patel Sanjiv | President and CEO |
Jul 09 '25 |
Sale |
3.57 |
61,379 |
219,123 |
765,288 |
Rahmer Peter | See remarks |
Apr 30 '25 |
Sale |
3.00 |
10,739 |
32,217 |
390,081 |
Rahmer Peter | See remarks |
Apr 28 '25 |
Sale |
3.17 |
1,364 |
4,324 |
400,820 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):